Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Nitric Oxide and Symptom Reduction in Schizophrenia

Nitric Oxide and Symptom Reduction in Schizophrenia Opinion Editorial Nitric Oxide and Symptom Reduction in Schizophrenia Joseph T. Coyle, MD In this issue of the journal, Hallak et al report results from a A remarkable finding was the persistent improvement in placebo-controlled clinical trial showing that infusion of symptoms for 2 weeks after the single dose of nitroprusside. sodium nitroprusside causes a rapid and persistent reduc- The authors rightfully express caution about this finding (the tion of symptoms in patients data were requested by the reviewers) because the blind had with schizophrenia who have been broken before this period of observation and the pa- Related article page 668 been symptomatically stabi- tients had undergone unblinded medication adjustments. lized with antipsychotic medications. The peer reviewers of However, such a persistent effect after a single-dose treat- the manuscript concurred that the study pointed to a poten- ment is not unprecedented. Recent research has demon- tially new avenue for pharmacologic intervention in schizo- strated that a single dose of the NMDA receptor antagonist ket- phrenia, although they recognized that the small number of amine when given to patients with drug-resistant depression patients studied was a serious limitation. It is true that the can produce a rapid improvement in mood http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Nitric Oxide and Symptom Reduction in Schizophrenia

JAMA Psychiatry , Volume 70 (7) – Jul 1, 2013

Loading next page...
 
/lp/american-medical-association/nitric-oxide-and-symptom-reduction-in-schizophrenia-QoJiWg12Oo

References (9)

Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2013.210
pmid
23699799
Publisher site
See Article on Publisher Site

Abstract

Opinion Editorial Nitric Oxide and Symptom Reduction in Schizophrenia Joseph T. Coyle, MD In this issue of the journal, Hallak et al report results from a A remarkable finding was the persistent improvement in placebo-controlled clinical trial showing that infusion of symptoms for 2 weeks after the single dose of nitroprusside. sodium nitroprusside causes a rapid and persistent reduc- The authors rightfully express caution about this finding (the tion of symptoms in patients data were requested by the reviewers) because the blind had with schizophrenia who have been broken before this period of observation and the pa- Related article page 668 been symptomatically stabi- tients had undergone unblinded medication adjustments. lized with antipsychotic medications. The peer reviewers of However, such a persistent effect after a single-dose treat- the manuscript concurred that the study pointed to a poten- ment is not unprecedented. Recent research has demon- tially new avenue for pharmacologic intervention in schizo- strated that a single dose of the NMDA receptor antagonist ket- phrenia, although they recognized that the small number of amine when given to patients with drug-resistant depression patients studied was a serious limitation. It is true that the can produce a rapid improvement in mood

Journal

JAMA PsychiatryAmerican Medical Association

Published: Jul 1, 2013

There are no references for this article.